Brincidofovir (CMX001, HDP CDV, HDPCDV)

Description: Brincidofovir (CMX-001, BCV, HDP-CDV, HDPCDV), a lipid-conjugated prodrug of Cidofovir, is a potent, orally bioavailable, and long-acting DNA polymerase inhibitor potentially for the treatment of cytomegalovirus, adenovirus, smallpox, and ebolavirus infections. Brincidofovir is a 3-hexadecyloxy-1-propanol (HDP) lipid conjugate of the acyclic nucleoside phosphonate cidofovir (CDV). Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as orally bioavailable bioavailability.